Abeona Therapeutics Inc. — Form 10-Q Summary
Reporting period: Quarter and six months ended June 30, 2018. Abeona is a clinical-stage biopharmaceutical company developing cell and gene therapies for rare genetic diseases, including EB-101 for RDEB and ABO-102/ABO-101 for Sanfilippo syndrome. Financial statements are unaudited.
Financial performance and liquidity
| Metric | Q2 2018 | Q2 2017 | Six months 2018 | Six months 2017 |
|---|---|---|---|---|
| Total revenue | $819,000 | $217,000 | $3.417 million | $403,000 |
| Operating expenses | $12.833 million | $8.657 million | $24.047 million | $14.127 million |
| Operating loss | $12.014 million | $8.440 million | $20.630 million | $13.724 million |
| Net loss | $11.700 million | $8.279 million | $20.163 million | $13.526 million |
| Basic and diluted loss per share | $0.25 | $0.21 | $0.43 | $0.34 |
- Revenue consisted mainly of Sanfilippo foundation grants: $802,000 in Q2 and $3.350 million for the six months. MuGard royalties were $17,000 and $67,000, respectively; no license revenue was reported in 2018.
- Research and development expense rose to $7.916 million for Q2 and $16.078 million for six months, driven largely by clinical/manufacturing work, staffing, and stock compensation. General and administrative expense also increased, to $4.627 million and $7.505 million, respectively.
- Cash and cash equivalents were $49.990 million at June 30, 2018; marketable securities were $69.852 million, bringing combined cash and securities to $119.842 million. Working capital was $116.043 million. Management said existing cash and equivalents would fund operating and capital needs for at least 12 months.
- Six-month operating cash use was $13.104 million; investing cash use was $76.775 million, including $69.852 million for short-term investments and $6.923 million in capital expenditures. Financing provided $2.399 million, mainly from option and warrant exercises. Cash, equivalents and restricted cash declined $87.480 million; much of the decline reflected purchases of marketable securities.
- Total liabilities were $5.783 million, consisting of accounts payable; the balance sheet reported no borrowings. Accumulated deficit was $376.292 million.
- Operating and net losses increased year over year. Revenue remains small relative to development costs; the filing does not provide a meaningful gross-margin measure.
Material changes and notable items
- Effective January 1, 2018, Abeona adopted ASC 606 using the modified retrospective method. Adoption increased opening stockholders’ equity by $3.663 million and eliminated recognition of previously deferred license revenue; reported 2018 results are therefore not fully comparable with 2017.
- R&D spending increased by $8.072 million and total operating expenses by $9.920 million for the first six months versus 2017. The company cited increased program development/manufacturing activity, hiring, and stock-based compensation.
- Property and equipment increased to $8.007 million from $1.374 million at year-end, alongside $6.923 million in first-half capital expenditures. The company announced in May the opening of its Cleveland GMP manufacturing facility.
- Foundation commitments could provide up to approximately $13.85 million for MPS IIIA/IIIB programs, subject to milestones. Abeona had received $3.4 million by June 30, 2018, recognized as revenue as related expenses were incurred.
Outlook, programs, and risks
- Management expects continued losses for several years while investing in research, preclinical work, clinical trials, and regulatory compliance; profitability is not assured. Management says additional financing may be needed and equity issuance could dilute existing holders.
- ABO-102 Phase 1/2: 11 patients had been dosed by June 30; two more were dosed after quarter-end, bringing the total to 13. The company reported biomarker reductions and stated the therapy was well tolerated, with no drug-related serious adverse events through more than 5,200 cumulative post-injection days as of the later update. These are clinical-trial findings, not proof of efficacy or approval.
- EB-101 Phase 1/2 results reported for seven patients and 42 graft treatments included greater than 50% wound healing in 100% of grafts at three months, 90% at six months, 63% at 12 months, and 81% at 24 months; the filing says a Phase 3 study is planned.
- Management stated that ABO-102 data, including expansion-cohort results, could support a BLA submission. This is a forward-looking expectation, not an approved filing or assured timeline. No formal financial guidance was provided.
- Key risks include clinical and regulatory uncertainty, manufacturing and commercialization execution, ongoing cash burn and financing needs, and uncertain product markets. Management reported no material changes to the 2017 Form 10-K risk factors, no material legal proceedings, and effective disclosure controls as of June 30.
- After quarter-end, Abeona announced commercial leadership changes, including a new Chief Commercial Officer and the COO’s planned departure effective September 30, 2018.
Important facts for investors to verify
- Updated ABO-102 safety, durability, clinical outcomes, patient follow-up, and the evidence required for any BLA submission.
- EB-101 Phase 3 design, timing, funding, and whether early wound-healing results are confirmed in larger studies.
- Actual cash burn, capital spending, milestone-based grant receipts, and the company’s runway beyond management’s stated 12-month horizon.
- Manufacturing capacity, readiness, costs, and execution at the Cleveland GMP facility.
- ASC 606 effects on revenue comparability and the terms, conditions, and remaining availability of foundation grants.